AmniSure, prescribed by obstetricians and gynecologists (OB/GYNs), is a point of need test designed to determine whether a pregnant woman is suffering from a rupture of fetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely.

The assay is also used by OB/GYNs, as part of cervical cancer prevention testing, to screen patients for human papillomavirus.

Qiagen chief executive officer Peer Schatz said the company is pleased to bring the AmniSure assay into its portfolio of solutions for point of need diagnostics.

"This very accurate diagnostic test contributes significant value in the management of pregnancy and adds to QIAGEN’s portfolio of tests and in particular for the OB/GYN market that also includes our gold-standard digene HPV Test," Schatz added.

Financial terms of the transaction have not been disclosed.